A potent synthetic agonist of GONADOTROPIN-RELEASING HORMONE with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central PRECOCIOUS PUBERTY and ENDOMETRIOSIS.
A metabolite of PROGESTERONE with a hydroxyl group at the 17-alpha position. It serves as an intermediate in the biosynthesis of HYDROCORTISONE and GONADAL STEROID HORMONES.
Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.
A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.
Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.
Receptors with a 6-kDa protein on the surfaces of cells that secrete LUTEINIZING HORMONE or FOLLICLE STIMULATING HORMONE, usually in the adenohypophysis. LUTEINIZING HORMONE-RELEASING HORMONE binds to these receptors, is endocytosed with the receptor and, in the cell, triggers the release of LUTEINIZING HORMONE or FOLLICLE STIMULATING HORMONE by the cell. These receptors are also found in rat gonads. INHIBINS prevent the binding of GnRH to its receptors.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity.
Peptides, natural or synthetic, that stimulate the release of PITUITARY HORMONES. They were first isolated from the extracts of the HYPOTHALAMUS; MEDIAN EMINENCE; PITUITARY STALK; and NEUROHYPOPHYSIS. In addition, some hypophysiotropic hormones control pituitary cell differentiation, cell proliferation, and hormone synthesis. Some can act on more than one pituitary hormone.
NATIONAL LIBRARY OF MEDICINE service for health professionals and consumers. It links extensive information from the National Institutes of Health and other reviewed sources of information on specific diseases and conditions.
It is a form of protection provided by law. In the United States this protection is granted to authors of original works of authorship, including literary, dramatic, musical, artistic, and certain other intellectual works. This protection is available to both published and unpublished works. (from Circular of the United States Copyright Office, 6/30/2008)
Patient health knowledge related to medications including what is being used and why as well as instructions and precautions.
Services providing pharmaceutic and therapeutic drug information and consultation.
Societies whose membership is limited to pharmacists.
Advanced programs of training to meet certain professional requirements in fields other than medicine or dentistry, e.g., pharmacology, nutrition, nursing, etc.
I'm sorry for any confusion, but the term "Maryland" is not a recognized medical term with a specific definition in the medical field. It refers to a state in the United States. If you have any questions about a medical condition or treatment, I would be happy to try and help answer those!

A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study. (1/29)

The use of gonadotrophin-releasing hormone analogues (GnRHa) has resulted in improved pregnancy rates in in-vitro fertilization (IVF) treatment cycles. Traditionally, short-acting analogues have been employed because of concerns over long-acting depot preparations causing profound suppression and luteal phase defects adversely affecting pregnancy and miscarriage rates. We randomized 60 IVF patients to receive a short-acting GnRHa, nafarelin or buserelin, or to receive a depot formulation, leuprorelin, all commenced in the early follicular phase and compared their effects on hormonal suppression and clinical outcome. We found that on day 15 of administration there was a significant difference in the suppression of oestradiol from initial concentrations, when patients on buserelin were compared with patients on nafarelin or leuprorelin (54 versus 72 and 65%; P < 0.05) and also in the number of patients satisfactorily suppressed, (80 versus 90 and 90%; P < 0.05), though there were no differences between the analogues by day 21. Similarly there was no difference in hormonal suppression during the stimulation phase or in implantation, pregnancy or miscarriage rates in comparing the three agonists. We conclude that with nafarelin and leuprorelin, stimulation with gonadotrophins may begin after 2 weeks of suppression and that long-acting GnRHa are as effective as short-acting analogues with no detrimental effects on the luteal phase.  (+info)

A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. (2/29)

A prospective, randomized, double-blind, multicentre (n = 5) study was conducted to compare the influence of either a 100 or 200 IU daily fixed-dose regimen of recombinant follicle stimulating hormone (FSH) on the number of oocytes retrieved and the total dose used in down-regulated women undergoing ovarian stimulation. Fertilization was done by intracytoplasmic sperm injection or conventional in-vitro fertilization. A total of 199 women were treated with FSH, 101 subjects with 100 IU and 98 subjects with 200 IU. In subjects of the 200 IU treatment group, significantly more oocytes were retrieved compared to the 100 IU group (10.6 versus 6.2 oocytes, P < 0.001). The total dose needed to develop at least three follicles with a diameter of > or = 17 mm was significantly lower in the 100 IU treatment group (1114 IU versus 1931 IU, P < 0.001). In the low-dose group, significantly lower serum concentrations of oestradiol, progesterone and FSH were observed at the day of human chorionic gonadotrophin administration. Although more cycle cancellations due to low response were seen in the 100 IU group (n = 24 versus n = 3), the clinical pregnancy rate per started cycle was similar (24.7% in the 100 IU group versus 23.3% in the 200 IU group). In the high-dose group, more side-effects, in particular more cases of ovarian hyperstimulation syndrome, were noted. It is concluded that compared to 200 IU, the use of a 100 IU fixed dose is less efficacious in terms of the number of oocytes retrieved, but more efficient as indicated by a lower total dose.  (+info)

Ovarian response to repeated controlled stimulation in in-vitro fertilization cycles in patients with ovarian endometriosis. (3/29)

In-vitro fertilization (IVF) is an effective infertility treatment for women with endometriosis, but most women need to undergo several cycles of treatment to become pregnant. This case-control study was designed to assess how consistently women with ovarian endometriosis respond to ovarian stimulation in consecutive treatment cycles compared to women with tubal infertility. We compared outcome measures in 40 women with a history of surgically confirmed ovarian endometriosis and 80 women with tubal infertility, all of whom had at least three IVF treatment cycles. The groups were matched for age and early follicular follicle stimulating hormone (FSH) concentration at their first IVF cycle. Outcome measures included number of follicles, number of oocytes, peak oestradiol concentration and number of FSH ampoules required per follicle. Cumulative pregnancy and live birth rates were calculated in both groups. The ovarian endometriosis group had a significantly poorer ovarian response and required significantly more ampoules of FSH per cycle, a difference that became greater with each subsequent cycle. However, cumulative pregnancy (63.3 versus 62.6% by fifth cycle) and live birth (46.8 versus 50.9% by fifth cycle) rates were similar in both groups. In conclusion, despite decreased ovarian response to FSH, ovarian endometriosis does not decrease the chances of successful IVF treatment.  (+info)

Is endometrial pre-treatment of value in improving the outcome of transcervical resection of the endometrium? (4/29)

The aim of this study was to determine whether or not the use of medical pre-treatment of the endometrium improves the outcome of transcervical resection of the endometrium with regards to long-term operative outcome, histological findings and patient satisfaction. A prospective randomized trial comparing three endometrial pre-treatment agents (danazol, medroxyprogesterone acetate or nafarelin) with no pre-treatment was conducted. The main outcome measures were: (i) thickness of the endometrium and myometrium resected; (ii) histological stage of the endometrium at the time of operation; (iii) the presence or absence of menses and (iv) patient satisfaction 1 year post-operatively. Of the three pre-treatments studied, danazol produced a lower median endometrial thickness than the control, showed the greatest ability to induce atrophy of the endometrial glands and stroma (not statistically significant) and produced the highest rate of amenorrhoea (not different to the control). Danazol and nafarelin produced significantly lower median endometrial thickness than no pre-treatment. There were, however, no significant differences in the rates of amenorrhoea in any of the pre-treatment groups compared with that in the control group. No improvement in clinical outcome or patient satisfaction is conferred by the use of medical pre-treatments if transcervical resection of the endometrium is performed in the proliferative phase of the menstrual cycle.  (+info)

Efficacy of nafarelin in assisted reproductive technology: a meta-analysis. (5/29)

A systematic review identified nine randomized, controlled trials (both published and unpublished) which assessed the efficacy of nafarelin during IVF compared with other gonadotrophin-releasing hormone (GnRH) agonists. The trials included 1,014 women (nafarelin n = 597) in protocols employing three different dosage regimens, long and short stimulation protocols, and three comparative GnRH agonists (buserelin n = 348; triptorelin n = 14, and leuprolide n = 55). The meta-analysis of the data showed that pregnancy rates per embryo transfer with nafarelin were equivalent to those obtained with other GnRH agonists. Nafarelin and other agonists were also comparable in terms of several intermediate IVF outcomes, including fertilization rates, number of oocytes retrieved, peak oestradiol concentrations, and cycle cancellations. Women treated with nafarelin required fewer ampoules of human menopausal gonadotrophin (HMG)/FSH for ovarian stimulation and fewer days of stimulation. Safety results from both the meta-analysis and a qualitative analysis of 12 additional reports suggested that adverse effects were within the accepted tolerance range; the most frequent adverse effects were hypo-oestrogenic symptoms. In conclusion, the overall efficacy of nafarelin was equivalent to that of other GnRH agonists. The possibility that the reduced gonadotrophin requirements in women taking nafarelin will translate into cost savings per IVF treatment cycle requires further study.  (+info)

Utero-ovarian blood flow characteristics of pituitary desensitization. (6/29)

BACKGROUND: Down-regulation in assisted reproduction treatment cycles is monitored by suppression of ovarian/pituitary hormones and/or measurement of endometrial thickness. METHODS: This prospective longitudinal study reports on utero-ovarian characteristics of pituitary desensitization. A total of 75 patients were recruited; 32 had IVF treatment, 20 frozen--thawed embryo transfer cycles and 23 patients were recipients of donated oocytes. All received early follicular-phase down-regulation and had colour flow Doppler velocimetry of the utero-ovarian arteries < or =3 days before the start of menses and after 21 days of gonadotrophin-releasing hormone (GnRH) analogue treatment. Ovarian volume, endometrial thickness, pituitary and ovarian hormone concentrations were recorded at each scan. RESULTS: Significant changes (P < 0.05) were noted in these and utero-ovarian vasculature during the down-regulation period, with good correlation between resistance index and oestradiol estimations. Neither the type of GnRH analogue nor age influenced the changes in utero-ovarian blood flow. Ovarian artery resistance index was the best Doppler predictor for pituitary suppression and a mean discriminatory cut-off value of 0.867 +/- 0.025 was found to have the highest specificity and positive predictive value. CONCLUSIONS: This study has, for the first time, defined cut-off values for satisfactory pituitary suppression with high positive predictive value and specificity in an early follicular phase long protocol of GnRH analogue down-regulation using colour flow Doppler.  (+info)

Prospective randomized comparison of ovarian blockade with nafarelin versus leuprolide during ovarian stimulation with recombinant FSH in an ICSI program. (7/29)

PURPOSE: A prospective study was conducted to compare the efficiency of ovarian blockade with nafarelin versus leuprolide in a population whose indication for assisted reproduction was the male factor METHODS: A total of 238 patients were assigned at random to two types of treatment: Group I (119 aspirations), nafarelin (Synarel, Searle), 200 microg by the nasal route twice a day, and Group II (119 aspirations), leuprolide acetate (Lupron, Abbott), 0.5 mg by the subcutaneous route once a day. Both types of blockade were started during the 2nd phase (21st day of the menstrual cycle) and were continued until the day of HCG (5,000-10,000 IU). All patients received a fixed dose of recombinant FSH for 7 days and on the 8th day of stimulation the doses started to be adapted according to ovarian response. RESULTS: Patients' age did not differ (p = 0.93) between Group 1 (34.1 +/- 3.79) and Group II (34 +/- 4.64). The number of oocytes retrieved from Group I (10.5 +/- 5.93) was also similar (p = 0.57) to that retrieved from Group II (10.2 +/- 6.36). In addition, there was no difference (p = 0.58) in the number of oocytes retrieved at Metaphase II between Group I (8.2 +/- 4.61) and Group II (7.9 +/- 5.2). Fertilization rates and embryo scores were similar (p = 0.81 and p = 0.25, respectively) for Group I (67.5% +/- 21.3 and 34.4% +/- 14.4) and Group II (68.1% +/- 23and32.2% +/- 14.7, respectively). Inaddition, pregnancy rates per puncture and per embryo transfer and implantation rates were similar for Group I (30.2, 31.3, and 16.2%, respectively) then compared with Group 11(24.4, 25.2, and 12.6%, respectively) (p = 0.38, p = 0.37, and p = 0.22, respectively). CONCLUSIONS: Implantation and pregnancy rates per puncture and per embryo transfer are not statistically significant in the nafarelin group when compared with leuprolide group.  (+info)

In-vivo ovarian androgen responses to recombinant FSH with and without recombinant LH in polycystic ovarian syndrome. (8/29)

BACKGROUND: Effects of exogenous LH on ovarian androgen secretion during ovulation induction have not been clearly characterized in polycystic ovarian syndrome (PCOS). The purpose of this study was to compare androgen secretion in PCOS women during ovarian stimulation with either recombinant FSH (rFSH) alone or combined with recombinant LH (rLH). METHODS: Clomiphene-resistant women with PCOS were allocated, in a factorial study design, to receive either daily injections of rFSH (n = 24) or rFSH + rLH (n = 24) in a 1:1 ratio starting: (i) on day 2-3 of progestogen-induced menses (n = 8); (ii) after 6 weeks of GnRH agonist treatment (nafarelin, 400 micro g twice daily; n = 8); or (iii) after nafarelin treatment as in (ii) plus dexamethasone (n = 8). The effects of rFSH with rFSH + rLH under these three hormone conditions on serum LH, 17alpha-hydroxyprogesterone (17-OHP), androstenedione (DeltaDelta(4)) and testosterone were contrasted by analysis of variance with specific treatment days as a repeated measures factor. RESULTS: Pre-study hormone levels were similar for all groupings. Nafarelin significantly suppressed LH levels, which remained at the lower limit of assay sensitivity (0.5 IU/l) during stimulation with rFSH but increased significantly to >1 but <2 IU/l when rLH was added. As expected, 17-OHP, DeltaDelta(4) and testosterone levels fell following nafarelin treatment. Dexamethasone further suppressed 17-OHP, DeltaDelta(4) and testosterone levels and unmasked a small but significant rise in these ovarian steroids 24 h following the first dose of rFSH + rLH, a rise that was absent with rFSH alone. Secretion of these steroids then appeared to 'catch-up' after 5 days of rFSH stimulation. CONCLUSIONS: Despite profound LH, 17-OHP, DeltaDelta(4) and testosterone suppression, comparable E(2) response, follicle development and successful pregnancies in PCOS subjects receiving rFSH alone to those receiving rFSH + rLH would argue that circulating LH at levels as low as 0.5 IU/l are sufficient to sustain adequate follicle development and function when FSH is present in abundance. Whether the observed dichotomy between rFSH and rFSH + rLH treatment in temporal secretion patterns reflects a greater reliance on evolving paracrine mechanisms as the follicles mature under profound LH suppression remains to be explored but may influence the optimal LH threshold for ovulation induction in PCOS.  (+info)

Nafarelin is a synthetic decapeptide analog of the natural gonadotropin-releasing hormone (GnRH). It is primarily used as a nasal spray for the treatment of central precocious puberty in children and endometriosis in adults.

In medical terms, Nafarelin is defined as:

A synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) used in the treatment of central precocious puberty and endometriosis. It acts as a potent agonist of GnRH receptors, leading to an initial increase in the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), followed by downregulation of these receptors and a decrease in FSH and LH secretion. This results in decreased gonadal steroid production, including estrogen and testosterone, which helps to control the symptoms of central precocious puberty and endometriosis.

Nafarelin is available under the brand name Synarel and is administered as a nasal spray. It is important to note that Nafarelin can cause side effects such as hot flashes, headaches, and mood changes, and it may also affect bone growth in children with central precocious puberty. Therefore, it should be used under the close supervision of a healthcare provider.

17-α-Hydroxyprogesterone is a naturally occurring hormone produced by the adrenal glands and, in smaller amounts, by the ovaries and testes. It is an intermediate in the biosynthesis of steroid hormones, including cortisol, aldosterone, and sex hormones such as testosterone and estrogen.

In a medical context, 17-α-Hydroxyprogesterone may also refer to a synthetic form of this hormone that is used in the treatment of certain medical conditions. For example, a medication called 17-alpha-hydroxyprogesterone caproate (17-OHP) is used to reduce the risk of preterm birth in women who have previously given birth prematurely. It works by suppressing uterine contractions and promoting fetal lung maturity.

It's important to note that 17-alpha-Hydroxyprogesterone should only be used under the supervision of a healthcare provider, as it can have side effects and may interact with other medications.

Hormones are defined as chemical messengers that are produced by endocrine glands or specialized cells and are transported through the bloodstream to tissues and organs, where they elicit specific responses. They play crucial roles in regulating various physiological processes such as growth, development, metabolism, reproduction, and mood. Examples of hormones include insulin, estrogen, testosterone, adrenaline, and thyroxine.

Gonadotropin-Releasing Hormone (GnRH), also known as Luteinizing Hormone-Releasing Hormone (LHRH), is a hormonal peptide consisting of 10 amino acids. It is produced and released by the hypothalamus, an area in the brain that links the nervous system to the endocrine system via the pituitary gland.

GnRH plays a crucial role in regulating reproduction and sexual development through its control of two gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These gonadotropins, in turn, stimulate the gonads (ovaries or testes) to produce sex steroids and eggs or sperm.

GnRH acts on the anterior pituitary gland by binding to its specific receptors, leading to the release of FSH and LH. The hypothalamic-pituitary-gonadal axis is under negative feedback control, meaning that when sex steroid levels are high, they inhibit the release of GnRH, which subsequently decreases FSH and LH secretion.

GnRH agonists and antagonists have clinical applications in various medical conditions, such as infertility treatments, precocious puberty, endometriosis, uterine fibroids, prostate cancer, and hormone-responsive breast cancer.

Precocious puberty is a medical condition where the onset of sexual maturation occurs at an unusually early age, typically before the age of 8 in girls and before the age of 9 in boys. It is characterized by the development of secondary sexual characteristics such as breast development or growth of facial hair, as well as the start of menstruation in girls. This condition can be caused by various factors including central nervous system abnormalities, genetic disorders, or exposure to certain hormones. Early diagnosis and treatment are important to prevent potential negative effects on growth, bone health, and psychosocial development.

LHRH (Luteinizing Hormone-Releasing Hormone) receptors are a type of G protein-coupled receptor found on the surface of certain cells in the body, most notably in the anterior pituitary gland. These receptors bind to LHRH, a hormone that is produced and released by the hypothalamus in the brain.

When LHRH binds to its receptor, it triggers a series of intracellular signaling events that ultimately lead to the release of two other hormones from the anterior pituitary gland: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones play critical roles in regulating reproductive function, including the development and maturation of sex cells (sperm and eggs), the production of sex steroid hormones (such as testosterone and estrogen), and the regulation of the menstrual cycle in females.

Disorders of the LHRH receptor or its signaling pathway can lead to a variety of reproductive disorders, including precocious puberty, delayed puberty, and infertility.

An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.

Luteinizing Hormone (LH) is a glycoprotein hormone, which is primarily produced and released by the anterior pituitary gland. In women, a surge of LH triggers ovulation, the release of an egg from the ovaries during the menstrual cycle. During pregnancy, LH stimulates the corpus luteum to produce progesterone. In men, LH stimulates the testes to produce testosterone. It plays a crucial role in sexual development, reproduction, and maintaining the reproductive system.

Pituitary hormone-releasing hormones (PRHs), also known as hypothalamic releasing hormones or hypothalamic hormones, are small neuropeptides produced and released by the hypothalamus - a small region of the brain. These hormones play crucial roles in regulating the secretion and release of various pituitary hormones, which in turn control several essential bodily functions, including growth, development, metabolism, stress response, reproduction, and lactation.

There are several PRHs, each with a specific target pituitary hormone:

1. Thyrotropin-releasing hormone (TRH): Stimulates the release of thyroid-stimulating hormone (TSH) from the anterior pituitary gland, which then promotes the production and release of thyroid hormones.
2. Gonadotropin-releasing hormone (GnRH): Regulates the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary gland, which are essential for reproductive functions.
3. Corticotropin-releasing hormone (CRH): Stimulates the release of adrenocorticotropic hormone (ACTH) from the anterior pituitary gland, which then promotes the production and release of cortisol and other glucocorticoids from the adrenal glands.
4. Growth hormone-releasing hormone (GHRH): Stimulates the release of growth hormone (GH) from the anterior pituitary gland, which is essential for growth, development, and metabolism regulation.
5. Somatostatin or growth hormone-inhibiting hormone (GHIH): Inhibits the release of GH from the anterior pituitary gland and also suppresses the secretion of thyroid hormones.
6. Prolactin-releasing hormone (PRH) or prolactin-releasing factor (PRF): Stimulates the release of prolactin from the anterior pituitary gland, which is essential for lactation and reproductive functions.
7. Prolactin-inhibiting hormone (PIH) or dopamine: Inhibits the release of prolactin from the anterior pituitary gland.

These releasing hormones and inhibitory hormones work together to maintain a delicate balance in various physiological processes, including growth, development, metabolism, stress response, and reproductive functions. Dysregulation of these hormonal systems can lead to various endocrine disorders and diseases.

MedlinePlus is not a medical term, but rather a consumer health website that provides high-quality, accurate, and reliable health information, written in easy-to-understand language. It is produced by the U.S. National Library of Medicine, the world's largest medical library, and is widely recognized as a trusted source of health information.

MedlinePlus offers information on various health topics, including conditions, diseases, tests, treatments, and wellness. It also provides access to drug information, medical dictionary, and encyclopedia, as well as links to clinical trials, medical news, and patient organizations. The website is available in both English and Spanish and can be accessed for free.

Copyright is a legal concept that gives the creator of an original work exclusive rights to its use and distribution, usually for a limited period of time. In the medical field, copyright protection can apply to various works such as medical textbooks, journal articles, educational materials, software, and multimedia presentations. It is important to note that copyright law seeks to strike a balance between protecting the rights of creators and promoting the progress of science and knowledge by allowing for limited use of copyrighted material under certain circumstances, such as fair use.

It's worth mentioning that while copyright protection can apply to medical works, there are also exceptions and limitations to copyright law that may allow for the use of copyrighted material without permission from the copyright owner in certain situations. For example, in the United States, the "fair use" doctrine allows for limited use of copyrighted material without obtaining permission from the copyright owner, depending on factors such as the purpose and character of the use, the nature of the copyrighted work, the amount and substantiality of the portion used, and the effect of the use upon the potential market for or value of the copyrighted work.

When using medical works that are protected by copyright, it is important to obtain permission from the copyright owner or ensure that the use falls under an exception or limitation to copyright law, such as fair use, in order to avoid infringing on the exclusive rights of the copyright owner.

Patient medication knowledge, also known as patient medication literacy or medication adherence, refers to the ability of a patient to understand and effectively communicate about their medications, including what they are for, how and when to take them, potential side effects, and other important information. This is an essential component of medication management, as it allows patients to properly follow their treatment plans and achieve better health outcomes. Factors that can affect patient medication knowledge include age, education level, language barriers, and cognitive impairments. Healthcare providers play a key role in promoting patient medication knowledge by providing clear and concise instructions, using visual aids when necessary, and regularly assessing patients' understanding of their medications.

Drug Information Services (DIS) are specialized resources within healthcare systems, typically staffed by clinical pharmacists and pharmacy residents, that provide evidence-based information and analysis about medications to healthcare professionals and patients. The primary goal of DIS is to optimize medication use and improve patient outcomes through the provision of accurate, unbiased, and timely information on drug therapy.

DIS commonly provide a range of services, including:

1. Answering medication-related questions from healthcare providers, such as physicians, nurses, and other pharmacists, regarding drug interactions, dosing, adverse effects, and therapeutic alternatives.
2. Developing and maintaining formulary management systems to ensure the safe and cost-effective use of medications within a healthcare institution or system.
3. Providing patient education materials and resources on medication therapy, including proper administration techniques, potential side effects, and storage requirements.
4. Conducting ongoing literature evaluations and synthesizing evidence-based recommendations for medication use in various clinical scenarios.
5. Collaborating with healthcare teams to develop and implement guidelines, policies, and procedures related to medication management and safety.
6. Offering educational programs and resources for healthcare professionals and students to enhance their knowledge of pharmacotherapy and medication safety practices.
7. Participating in multidisciplinary committees focused on improving medication use processes, reducing medication errors, and promoting patient safety.

DIS are essential components of modern healthcare systems, as they help ensure the safe, effective, and efficient use of medications for improved patient outcomes.

A pharmaceutical society is a professional organization that represents and serves the interests of pharmacists and the pharmaceutical industry in a given society or country. The primary objective of these societies is to promote the advancement of the profession of pharmacy, including education, research, and practice. They also work to ensure the safe and effective use of medications, advocate for evidence-based policies and practices, and provide resources and support to their members.

Pharmaceutical societies may engage in various activities, such as:

1. Developing guidelines and standards for pharmacy education and practice.
2. Providing continuing education programs for pharmacists.
3. Conducting research and disseminating knowledge related to pharmacy and medication use.
4. Advocating for policies that promote the safe and effective use of medications.
5. Collaborating with other healthcare professionals, regulatory bodies, and industry partners to improve patient outcomes.
6. Providing resources and support to members, including career development opportunities and networking events.

Examples of pharmaceutical societies include the American Pharmacists Association (APhA), the Royal Pharmaceutical Society (RPS) in the UK, and the International Pharmaceutical Federation (FIP).

A non-medical internship is not specifically related to the field of medicine. It generally refers to an organized period of work experience, often temporary, in which a person typically a student or trainee, gains practical knowledge and skills in a particular industry or profession. The intern is supervised and mentored by experienced professionals in the field. Non-medical internships can be found in various sectors such as business, engineering, law, education, media, technology, and many others. They provide an opportunity to apply theoretical knowledge gained in the classroom to real-world situations and help interns develop professional competencies and networks.

I'm sorry for any confusion, but "Maryland" is a proper noun and does not have a medical definition. It is a state located in the Mid-Atlantic region of the United States. However, if you are referring to a specific medical term or concept that includes "Maryland," could you please provide more context? I'll do my best to help with accurate information based on the provided context.

... is marketed for medical use in both its free base (nafarelin) and acetate salt (nafarelin acetate) forms. Nafarelin ... A bottle of nafarelin nasal spray (brand name Synarel) lasts for about 7 days at a dosage of 1,600 μg/day. Nafarelin is used to ... Nafarelin is available in the form of a 0.2% nasal spray for use one, two, or three times per day. Each bottle of nafarelin ... Nafarelin is eliminated 44 to 55% in urine and 18.5 to 44.2% in feces. Nafarelin is a GnRH analogue, or a synthetic analogue of ...
... , sold under the brand name Gonazon, is a gonadotropin-releasing hormone agonist (GnRH agonist) medication ... In addition to its use in mammals, azagly-nafarelin has been approved for use in aquaculture fish, specifically to control ...
These include the GnRH agonists buserelin, histrelin, leuprorelin, nafarelin, and triptorelin. GnRH agonists are available and ...
The agents nafarelin and triptorelin are agonists with single substitutions at position 6. Chemical structures of GnRH agonists ... GnRH agonists routinely used for this purpose are: buserelin, leuprorelin, nafarelin, and triptorelin. Final maturation ... nafarelin GnRH agonists are pregnancy category X drugs. Common side effects of the GnRH agonists and antagonists include ... nafarelin, and triptorelin. GnRH agonists that are used mostly or exclusively in veterinary medicine include deslorelin and ...
Nafarelin, marked as Synarel, is also occasionally prescribed in the form of nasal spray. These drugs are all approved by the ... At the same time, nafarelin is an exception in which its prescription is a nasal spray, and some may be implanted into fats. In ...
A newer hormonal intervention used in Europe is the use of GnRH analogs such as nafarelin or buserelin; the success rates and ...
GnRH analogues like nafarelin and busurelin are used for the treatment of anovulatory infertility, hypogonadotropic ...
Fertility and sterility, 1999 MD Hornstein, R Hemmings, AA Yuzpe Use of nafarelin versus placebo after reductive laparoscopic ... LR Heinrichs Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated ...
The medication is one of only two medically used GnRH analogues that are available as nasal sprays, the other being nafarelin. ...
H01CA02 Nafarelin QH01CA90 Buserelin QH01CA91 Fertirelin QH01CA92 Lecirelin QH01CA93 Deslorelin QH01CA94 Azagly-nafarelin ...
Whereas nafarelin acetate in a nasal spray induces a short lived LH surge that is high enough to induce ovulation in large ... Natural or Mini-IVF, but without the use of hCG to trigger ovulation, instead the GnRH agonist Synarel (nafarelin acetate) in a ...
... nafarelin (INN) Nafazair (Bausch & Lomb) nafazatrom (INN) nafcaproic acid (INN) nafcillin (INN) nafenodone (INN) nafenopin (INN ...
... nafarelin MeSH D06.472.420.740.320.790 - triptorelin MeSH D06.472.420.740.530 - msh-releasing hormone MeSH D06.472.420.740.720 ...
Azagly-nafarelin Buserelin Deslorelin Fertirelin GnRH Gonadorelin Goserelin Histrelin Lecirelin Leuprorelin Nafarelin Peforelin ...
Buserelin Deslorelin Fertirelin Gonadorelin Goserelin Histrelin Lecirelin Leuprorelin Nafarelin Peforelin Triptorelin A ...
... nafarelin MeSH D12.644.456.460.800 - triptorelin MeSH D12.644.456.580 - leupeptins MeSH D12.644.456.650 - netropsin MeSH ...
Nafarelin is marketed for medical use in both its free base (nafarelin) and acetate salt (nafarelin acetate) forms. Nafarelin ... A bottle of nafarelin nasal spray (brand name Synarel) lasts for about 7 days at a dosage of 1,600 μg/day. Nafarelin is used to ... Nafarelin is available in the form of a 0.2% nasal spray for use one, two, or three times per day. Each bottle of nafarelin ... Nafarelin is eliminated 44 to 55% in urine and 18.5 to 44.2% in feces. Nafarelin is a GnRH analogue, or a synthetic analogue of ...
Fass environmental information for Synarela (nafarelin) from Pfizer (downloaded 2023-08-25). ...
Nafarelin is the generic name of the drug and its INN and BAN, while nafaréline is its DCF and nafarelin acetate is its USAN, ... Nafarelin is marketed for medical use in both its free base (nafarelin) and acetate salt (nafarelin acetate) forms.[9] ... "Nafarelin Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 11 November 2021.. *↑ 9.0 9.1 9.2 9.3 9.4 9.5 9.6 Index ... Nafarelin is a GnRH analogue, or a synthetic analogue of GnRH.[3][2][20] It is a decapeptide and is also known as [6-D-(2- ...
Nafarelin. Most other Common Side Effects: Hot flashes, vaginal dryness, headaches, mood changes, breast enlargement, and ...
SYNAREL (nafarelin acetate) spray, metered. NDC Code(s): 0025-0166-08 *Packager: Pfizer Laboratories Div Pfizer Inc ...
A systematic review discusses the efficacy of this approach to controlling endometriosis-related pain.
Check with your doctor right away if you have pain or tenderness in the upper stomach, pale stools, dark urine, loss of appetite, nausea, vomiting, unusual tiredness or weakness, or yellow eyes or skin. These could be symptoms of a serious liver problem. This medicine may cause serious lung or breathing problems (eg, interstitial lung disease, pneumonitis). Check with your doctor right away if you have chest pain, chills, cough, fever, general feeling of discomfort or illness, thickening of bronchial secretions, or trouble breathing. Check with your doctor right away if blurred vision, dizziness, nervousness, headache, pounding in the ears, or slow or fast heartbeat occurs during or after treatment with this medicine. These can be symptoms of hypertension (high blood pressure). This medicine can cause changes in your heart rhythm, including a condition called QT prolongation. Call your doctor right away if you have dizziness, fainting, or slow, fast, pounding, or uneven heartbeats. This medicine ...
Detailed drug Information for Duo-Vil 2-25. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
Detailed drug Information for Toremifene. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
This medicine comes with a patient information insert. Read and follow these instructions carefully. Ask your doctor or pharmacist if you have any questions. The solution comes in small containers that are only used one time. Throw the empty container away after putting the medicine into your ear(s). This medicine should be used only inside the ear. Do not put it in the eyes or nose, and do not take it by mouth. If this medicine is swallowed by accident or gets into your eyes, call your doctor right away. It is important that the infected ear remain clean and dry. When bathing, avoid getting the infected ear wet. Avoid swimming unless your doctor has instructed you otherwise. To use the ear drops:. ...
Continuous advances have provided a new understanding of the diagnosis, staging, and treatment of metastatic and advanced prostate cancer. The earlier definition of advanced disease (bone metastasis and soft-tissue involvement) has also been improved.
Endometriosis causes endometrial tissue to grow outside of the womb, which can cause pain and fertility problems. Endometriosis pain varies from person to person, but can sometimes cause disabling pain, pain only associated with menstrual periods, pain during sex, or pain during a bowel movement.
Nafarelin Nasal Spray ... and causes infertility, pain before and during menstrual periods, pain during and after sexual ...
Nafarelin. *Triptorelin. 2.2 CORTICOTROPHINS AND THEIR RELEASING FACTORS, E.G.. *Corticorelin. 2.3 GROWTH HORMONE (GH), ITS ...
Nafarelin. Date of publication: 30/07/2015. *Naloxone. Date of publication: 05/04/2018 ...
Synarel®see Nafarelin Nasal Spray. *Syndros®see Dronabinol. *Synera® (containing lidocaine and tetracaine)see Lidocaine ...
... such as leuprolide and nafarelin, may help relieve the pain. Medroxyprogesterone is a progestin (a synthetic form of the female ...
The word Hormone comes means, to spur on which reflects how hormones act as catalysts for other chemical changes at the cellular level necessary for growth, development, and energy. Hormones are chemical messengers that carry and travel signals in the blood stream from 1 cell or glands to other tissues and organs to maintain chemical levels in the bloodstream that achieve homeostasis.
Lowest price on Prometrium medication. Buy at a cheaper price than in the US at our verified online Canadian pharmacy.
GnRH agonists include leuprolide (Lupron, Eligard, generic), nafarelin (Synarel), and goserelin (Zoladex) ...
Peters CA, Walsh PC: The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic ...
Supprelin® LA (Histrelin), Synarel® (Nafarelin), and Triptodur® (Triptorelin) Approval Criteria:. *An FDA approved diagnosis of ...
Gonadotropin-releasing hormone agonists (GnRH agonists), such as buserelin, nafarelin, and leuprolide, suppress hormones that ...
1.0-1.5 ug NAF/ kg/d for nafarelin or a nafarelin analog, based on recent studies (Concannon et al, unpublished). Pregnancy ...
Gonadotropin-releasing hormone (GnRH) agonists, including leuprolide (Lupron), nafarelin nasal (Synarel) and goserelin (Zoladex ...
24 months in the nafarelin group versus 11.7 months in the placebo group. Fifteen (31%) of 49 nafarelin-treated patients ... Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis 52nd Annual Meeting of the American- ... Our goal was to determine the effects of a repeated course of the gonadotropin-releasing hormone agonist nafarelin on symptoms ... To evaluate the efficacy of the GnRH agonist (GnRH-a) nafarelin compared with placebo administered for 6 months after reductive ...
24 months in the nafarelin group versus 11.7 months in the placebo group. Fifteen (31%) of 49 nafarelin-treated patients ... Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis 52nd Annual Meeting of the American- ... Our goal was to determine the effects of a repeated course of the gonadotropin-releasing hormone agonist nafarelin on symptoms ... To evaluate the efficacy of the GnRH agonist (GnRH-a) nafarelin compared with placebo administered for 6 months after reductive ...
... leuprorelin and nafarelin1. Some non-hormonal treatments for hot flushes, such as venlafaxine, can also cause hot flushes at ...

No FAQ available that match "nafarelin"

No images available that match "nafarelin"